aceclofenac 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory agents, ibufenac derivatives 43 89796-99-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aceclofenac
  • aceclofar
  • hifenac
  • Molecular weight: 354.18
  • Formula: C16H13Cl2NO4
  • CLOGP: 4.59
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 75.63
  • ALOGS: -5.25
  • ROTB: 7

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,IKBKB,ITK,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,STK33,TEK,TGFBR1,TTK 36
kinase-selectivity-class ACVR2B,AXL,BRAF,CDK9,DDR1,EPHB4,GRK2,MAP2K6,MAPK7,PDK4,SIK2,STK33 12
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.75
rat-kpuu-brain Rat brain Kpuu 0.015 % Moderate 0.75

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperreflexia 82.83 34.99 18 899 6639 90620891
Apraxia 63.25 34.99 12 905 2250 90625280
Perseveration 55.46 34.99 8 909 277 90627253
Vitreous detachment 38.51 34.99 8 909 2370 90625160
Myoclonus 37.77 34.99 12 905 19156 90608374
Drug interaction 35.06 34.99 26 891 276427 90351103

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cutaneous symptom 35.23 31.65 6 640 407 42620282
Meningioma 32.19 31.65 7 639 1720 42618969

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Amaurosis fugax 77.20 31.99 16 2184 2374 110584725
Hyperreflexia 64.31 31.99 18 2182 9467 110577632
Urinary tract disorder 53.23 31.99 14 2186 5830 110581269
Ocular discomfort 52.44 31.99 15 2185 8518 110578581
Apraxia 49.76 31.99 12 2188 3528 110583571
Haemorrhagic stroke 49.39 31.99 16 2184 13773 110573326
Perseveration 46.81 31.99 8 2192 419 110586680
Head discomfort 40.64 31.99 15 2185 18985 110568114
Altered state of consciousness 38.41 31.99 20 2180 57606 110529493
Haematuria 34.14 31.99 21 2179 82984 110504115
Generalised oedema 33.67 31.99 15 2185 30689 110556410
Eye pain 32.28 31.99 17 2183 50082 110537017
Vitreous detachment 32.20 31.99 8 2192 2657 110584442

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AB16 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Acetic acid derivatives and related substances
ATC M02AA25 MUSCULO-SKELETAL SYSTEM
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
Antiinflammatory preparations, non-steroids for topical use
MeSH PA D000700 Analgesics
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018501 Antirheumatic Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D018712 Analgesics, Non-Narcotic
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
CHEBI has role CHEBI:35481 non-narcotic analgesic
CHEBI has role CHEBI:35544 EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

M01AB Acetic acid derivatives and related substances 16 drugs
acemetacinalclofenacbufexamacbumadizonediclofenacdifenpiramideetodolacfentiazacindomethacinketorolaclonazolacoxametacin show all 16 →
M02AA Antiinflammatory preparations, non-steroids for topical use 28 drugs
bendazacbenzydaminebufexamacclofezonedexketoprofendiclofenacesflurbiprofenetofenamatefelbinacfentiazacfeprazoneflurbiprofen show all 28 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ankylosing spondylitis indication 9631008 DOID:7147
Rheumatoid arthritis indication 69896004 DOID:7148
Backache indication 161891005
Osteoarthritis indication 396275006
Adhesive capsulitis of shoulder indication 399114005 DOID:14188




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.37 acidic
pKa2 1.38 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme INHIBITOR DRUG LABEL SCIENTIFIC LITERATURE
Transthyretin Secreted Kd 5.92 CHEMBL
Mitogen-activated protein kinase 1 Kinase IC50 5.23 DRUG MATRIX
Aldose reductase Enzyme IC50 5.89 DRUG MATRIX

External reference:

IDSource
D01545 KEGG_DRUG
16689 RXNORM
C0050403 UMLSCUI
CHEBI:31159 CHEBI
CHEMBL93645 ChEMBL_ID
DB06736 DRUGBANK_ID
C056498 MESH_SUPPLEMENTAL_RECORD_UI
71771 PUBCHEM_CID
5608 INN_ID
RPK779R03H UNII
005957 NDDF
329923004 SNOMEDCT_US
391703003 SNOMEDCT_US
RPK779R03H INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ClanzaCR HUMAN PRESCRIPTION DRUG LABEL 1 65697-450 TABLET, FILM COATED 200 mg ORAL Export only 15 sections